PNC-28

≥98% HPLCCOA per batchCold-chain shippedIn-house synthesisResearch use only · not for human consumption

Price range: $34.99 through $54.99

Independently verified Tested by IRZC Laboratories Batch NHV26-B6374 · Purity 98.31 % HPLC · Issued 4 Aug 2026 · Cert COA-Y2ME-A7WT-9Verify at IRZCVerifyScan to verify

A p53-derived synthetic peptide combining the MDM2-binding domain of p53 (residues 17-26) with a membrane-penetrating sequence, researched for selective cancer cell necrosis via HDM2-dependent pore formation.

FormulaNot established
Mol. weightNot established
FormLyophilised powder
0 People watching this product now!
SKU: PEP-086 Category:

Molecular & analytical data

Verified chemistry and third-party reference identifiers for this compound.

Amino acid sequenceETFSDLWKLLKKWKMRRNQFWVKVQRG (27 residues: p53 residues 17-26, ETFSDLWKLL, fused at its carboxyl terminus to the membrane-residency/penetratin leader KKWKMRRNQFWVKVQRG)
Molecular formulaNot established
Molecular weightNot established
CAS number392661-17-5
PubChem CIDNot assigned (MedChemExpress product)
UniProt IDP04637 (TP53/p53)
Purity standard≥98%
Half-lifeShort (minutes; serum proteolysis)
BioavailabilityInjectable: moderate in vivo stability; rapid serum degradation
Origin / sourceSynthetic; first reported by Kanovsky et al., Proc Natl Acad Sci USA 2001;98(22):12438-12443, from the laboratories of Matthew R. Pincus and Josef Michl (Harbor Veterans Affairs Medical Center and SUNY Downstate Medical Center, Brooklyn, New York), designed from conformational analysis of the p53 MDM2-binding domain
Year discovered2001

Reconstitution calculator

Concentration, volume per draw, and the graduation it measures to. Open the full bench calculator with this vial loaded →

Concentration— mg/mL— mcg per unit
—Draw tounits on a U-100 syringe
—Volume / drawmL
—Complete drawsper vial

—

A U-100 insulin syringe reads 100 units per 1 mL. Figures describe the contents of a vial for laboratory handling reference only and are not dosing guidance.

Quality & verification

Every batch is characterised before release and ships with documentation.

≥98%HPLC purity
Short (minutes; serum proteolysis)Reported half-life
MS + HPLCIdentity & purity assay
Third-party testedBatches are tested by IRZC Laboratories — independent HPLC + mass-spec confirms identity and purity against that product’s release specification.
Batch-matched COAA certificate of analysis is issued per batch and matched to your vial’s lot number.
Cold-chain fulfilmentLyophilised product is packed with insulated, temperature-controlled shipping.
Controlled synthesisProduced under documented, reproducible in-house processes with lot traceability.

Storage & handling

Keep the peptide stable from delivery through reconstitution.

1
On arrivalStore the sealed, lyophilised vial frozen at −20°C, protected from light and moisture.
2
ReconstitutionAdd bacteriostatic water down the vial wall; swirl gently — do not shake. Use the calculator above to plan volume.
3
After mixingRefrigerate the reconstituted solution at 2–8°C and use within the stability window below.
4
HandlingWork in a clean area, wipe the stopper with alcohol, and avoid repeated freeze–thaw cycles.
Manufacturer storage note

Store lyophilized at -20°C. Protect from light. Limited stability in serum due to proteolysis.

Description

PNC-28 is a synthetic peptide derived from the MDM2-binding domain of the tumor suppressor protein p53 (residues 17-26: ETFSDLWKLL), linked to a membrane-penetrating sequence (penetratin/Antennapedia homeodomain sequence) at its C-terminus. The penetratin sequence enables cellular uptake, while the p53-derived domain targets HDM2 (human MDM2) protein, which is aberrantly expressed on the plasma membrane surface of cancer cells but not normal cells. Upon binding to membrane-expressed HDM2, PNC-28 induces formation of transmembrane pores leading to rapid tumor cell necrosis (within minutes to hours) rather than the slower process of apoptosis. This mechanism is selective: normal cells lack surface HDM2 expression and are therefore resistant to PNC-28 toxicity. Research has demonstrated PNC-28 activity against cancer cells from over 20 different human epithelial cancer lines including pancreatic, colon, lung, breast, and ovarian cancers in vitro, and inhibition of pancreatic cancer growth in vivo. The related peptide PNC-27 uses the same mechanism. PNC-28 has also been studied in combination with chemotherapy and as a model for peptide-based cancer immunotherapy. No human clinical trials have been completed.

Certificates of Analysis

Certificates of Analysis

Every batch of this peptide is tested before release. Find the batch number printed on your vial and verify or download its certificate.

Batch #IssuedPurityCertificate
NHV26-B6374
COA-Y2ME-A7WT-9
04 Aug 202698.31 % HPLCVerify at IRZC ↗

“Verify at IRZC” opens the laboratory’s own record for that certificate, on their site. Looking for an older batch we haven’t published? Email [email protected] with the batch number from your vial — we keep all certificates for 7 years.

Research & Literature
Reported in research literature — not usage guidance.

The information below summarises published preclinical and clinical research for scientific reference. NHOV products are sold strictly for laboratory research use only. Nothing here is medical advice, a recommendation, or an instruction for use in humans or animals.

Mechanism of action

Binds HDM2 (MDM2) expressed on cancer cell plasma membranes; forms transmembrane pores causing rapid necrotic cell lysis; selective for HDM2-expressing cancer cells; does not affect normal cells lacking surface HDM2; mechanism is pore formation rather than apoptotic pathway activation.

Primary uses / indications

Pancreatic cancer research, HDM2-targeted cancer therapy research, epithelial cancer research, anti-cancer peptide development, p53 pathway research

Typical dosage (reported)

Preclinical: variable doses in cancer models; no established human dose

Cycle duration (reported)

Research protocols only; no clinical dosing established

Administration route

Subcutaneous injection, Intratumoral injection (preclinical)

Side effects (reported)

No human safety data. Preclinical: selective for cancer cells in vitro. Theoretical: inflammatory response from necrotic tumor lysis (tumor lysis syndrome risk).

Contraindications

Active autoimmune conditions; theoretical concern for healthy tissue expressing any MDM2; pregnancy/breastfeeding

Drug interactions

Potential synergy with MDM2 antagonists (nutlin-3); theoretical interference with p53-MDM2 interaction drugs; caution with immunosuppressants

Reviews (0)
0 reviews
0
0
0
0
0

There are no reviews yet.

Be the first to review “PNC-28”

Your email address will not be published. Required fields are marked *

You have to be logged in to be able to add photos to your review.

Specifications

Identity

Full name / brand namesPNC-28 / p53-Derived Anticancer Peptide / p53(17-26)-Penetratin
CategoryAnti-Aging & Longevity
SubcategoryAnti-Cancer Research Peptide
Origin / sourceSynthetic; first reported by Kanovsky et al., Proc Natl Acad Sci USA 2001;98(22):12438-12443, from the laboratories of Matthew R. Pincus and Josef Michl (Harbor Veterans Affairs Medical Center and SUNY Downstate Medical Center, Brooklyn, New York), designed from conformational analysis of the p53 MDM2-binding domain
Year discovered2001

Chemistry

Amino acid sequenceETFSDLWKLLKKWKMRRNQFWVKVQRG (27 residues: p53 residues 17-26, ETFSDLWKLL, fused at its carboxyl terminus to the membrane-residency/penetratin leader KKWKMRRNQFWVKVQRG)
Molecular formulaNot established
Molecular weightNot established
CAS number392661-17-5
PubChem CIDNot assigned (MedChemExpress product)
UniProt IDP04637 (TP53/p53)
Purity standard≥98%

Pharmacokinetics

Half-lifeShort (minutes; serum proteolysis)
BioavailabilityInjectable: moderate in vivo stability; rapid serum degradation

Regulatory & research status

FDA statusNot FDA-approved. Research use only.
Prescription requiredResearch use only
Research statusPreclinical research; in vitro and animal models; no completed human clinical trials
Clinical trialsNo registered human clinical trials

References

Kanovsky M, Raffo A, Drew L, et al., "Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells", Proc Natl Acad Sci USA, 2001;98(22):12438-12443, DOI: 10.1073/pnas.211280698; Michl J, Scharf B, Schmidt A, et al., "PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo", International Journal of Cancer, 2006;119(7):1577-1585, DOI: 10.1002/ijc.22029; Pincus MR et al., "Anticancer peptide PNC-27 adopts an HDM2-binding conformation and kills cancer cells by binding to HDM2 in their membranes", PNAS, 2010, DOI: 10.1073/pnas.0909364107

Frequently asked questions

What is PNC-28?
A p53-derived synthetic peptide combining the MDM2-binding domain of p53 (residues 17-26) with a membrane-penetrating sequence, researched for selective cancer cell necrosis via HDM2-dependent pore formation.
How does PNC-28 work?
Reported in the research literature: Binds HDM2 (MDM2) expressed on cancer cell plasma membranes; forms transmembrane pores causing rapid necrotic cell lysis; selective for HDM2-expressing cancer cells; does not affect normal cells lacking surface HDM2; mechanism is pore formation rather than apoptotic pathway activation.
What PNC-28 dosage is used in research?
For laboratory research reference only, not usage guidance: Preclinical: variable doses in cancer models; no established human dose
What is the half-life of PNC-28?
The reported biological half-life of PNC-28 is approximately Short (minutes; serum proteolysis).
How should PNC-28 be stored and reconstituted?
NHOV ships PNC-28 as a lyophilised powder. Store unopened vials at −20 °C. Reconstitute with bacteriostatic water; once reconstituted, refrigerate at 2–8 °C, protect from light, and use within the bacteriostatic-water shelf window. Use the NHOV reconstitution calculator to find the exact volume for your target concentration.
What purity is NHOV's PNC-28?
NHOV PNC-28 is released against a specification of ≥98%, verified by HPLC with mass-spectrometry identity confirmation, and ships with a batch-specific Certificate of Analysis (COA) matched to the vial's lot number.
Is PNC-28 approved for human use?
No. PNC-28 is sold strictly for laboratory and scientific research use only. It is not for human or veterinary consumption and is not approved as a drug.